Dr. Drewry is Professor in the UNC Eshelman School of Pharmacy (University of North Carolina at Chapel Hill), the top-ranked pharmacy school in the US. An accomplished medicinal chemist, he moved to academia after a quarter century in the pharmaceutical industry at Glaxo and its successors. Dr. Drewry has a longstanding interest in the development of selective protein kinase inhibitors. As a champion of open-science chemical biology, he has driven the creation and free distribution of sets of chemical probes for kinase research. He interacts closely with other MSAB members and FCF grantees on strategies to therapeutically target the aberrant PKA signaling axis in FLC.